212 related articles for article (PubMed ID: 21724396)
1. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy.
Dahiya S; Givvimani S; Bhatnagar S; Qipshidze N; Tyagi SC; Kumar A
J Immunol; 2011 Sep; 187(5):2723-31. PubMed ID: 21810612
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.
Li H; Mittal A; Makonchuk DY; Bhatnagar S; Kumar A
Hum Mol Genet; 2009 Jul; 18(14):2584-98. PubMed ID: 19401296
[TBL] [Abstract][Full Text] [Related]
4. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.
Lourbakos A; Yau N; de Bruijn P; Hiller M; Kozaczynska K; Jean-Baptiste R; Reza M; Wolterbeek R; Koeks Z; Ayoglu B; de Klerk D; Campion G; Zaharieva I; Nadarajah VD; Nilsson P; Al-Khalili Szigyarto C; Muntoni F; Lochmüller H; Verschuuren JJ; Goemans N; Tulinius M; Niks EH; de Kimpe S; Aartsma-Rus A; 't Hoen PAC; Spitali P
Sci Rep; 2017 Dec; 7(1):17888. PubMed ID: 29263366
[TBL] [Abstract][Full Text] [Related]
6. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
7. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
[TBL] [Abstract][Full Text] [Related]
8. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.
Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
Am J Pathol; 2016 May; 186(5):1302-12. PubMed ID: 26963343
[TBL] [Abstract][Full Text] [Related]
9. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
10. Response to: Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
Spitali P; Aartsma-Rus A; 't Hoen PA
Neuromuscul Disord; 2015 May; 25(5):446-7. PubMed ID: 25795139
[No Abstract] [Full Text] [Related]
11. Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
Zocevic A; Rouillon J; Wong B; Servais L; Voit T; Svinartchouk F
Neuromuscul Disord; 2015 May; 25(5):444-6. PubMed ID: 25791581
[No Abstract] [Full Text] [Related]
12. Fibronectin is a serum biomarker for Duchenne muscular dystrophy.
Cynthia Martin F; Hiller M; Spitali P; Oonk S; Dalebout H; Palmblad M; Chaouch A; Guglieri M; Straub V; Lochmüller H; Niks EH; Verschuuren JJ; Aartsma-Rus A; Deelder AM; van der Burgt YE; 't Hoen PA
Proteomics Clin Appl; 2014 Apr; 8(3-4):269-78. PubMed ID: 24458521
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
14. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy.
Llano-Diez M; Ortez CI; Gay JA; Álvarez-Cabado L; Jou C; Medina J; Nascimento A; Jimenez-Mallebrera C
Neuromuscul Disord; 2017 Jan; 27(1):15-23. PubMed ID: 27979502
[TBL] [Abstract][Full Text] [Related]
15. Presence of metalloproteinases 2 and 9 and 8-OHdG in the fibrotic process in skeletal muscle of Mdx mice.
Souza LB; Maziero C; Lazzarin MC; Quintana HT; Tomé TC; Baptista VIA; de Oliveira F
Acta Histochem; 2020 Jan; 122(1):151458. PubMed ID: 31699373
[TBL] [Abstract][Full Text] [Related]
16. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
[TBL] [Abstract][Full Text] [Related]
17. Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan.
Kuraoka M; Aoki Y; Takeda S
Exp Anim; 2021 Nov; 70(4):419-430. PubMed ID: 34135266
[TBL] [Abstract][Full Text] [Related]
18. Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular dystrophy.
von Moers A; Zwirner A; Reinhold A; Brückmann O; van Landeghem F; Stoltenburg-Didinger G; Schuppan D; Herbst H; Schuelke M
Acta Neuropathol; 2005 Mar; 109(3):285-93. PubMed ID: 15616792
[TBL] [Abstract][Full Text] [Related]
19. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
[TBL] [Abstract][Full Text] [Related]
20. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
